Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Challenges in PNH and CAD Management Revealed through Educational Interventions over Three Years

Sumera Ackbarali, Tariqa Ackbarali, Katie Kowalski, Shirley D'Sa, Carlos M de Castro, Satheesh Chonat, Catherine M. Broome

Blood (2024) 144 (Supplement 1): 5087.

https://doi.org/10.1182/blood-2024-211593

Published: 2024

Journal Articles

Patient Satisfaction with Use of Complement Inhibitor Injector in Paroxysmal Nocturnal Hemoglobinuria in the United States

Brian Mulherin, Lawton Laurence, Carl Friddle, Jed Perler, Logan Locklear, Lisa Bailey, Amanda Cassidy, Dharmik Desai, Carlos M de Castro

Blood (2024) 144 (Supplement 1): 5673.

https://doi.org/10.1182/blood-2024-200983

Published: 2024

Journal Articles

Efficacy and Safety Is Maintained in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan for up to 3 Years

Carlos M de Castro, Brian Mulherin, Christopher J. Patriquin, Veena Selvaratnam, Raymond SM Wong, Richard J. Kelly, Lisa Tan, Peter Hillmen, Dale Zhang, Jessica Savage, Regis Peffault De Latour

Blood (2023) 142 (Supplement 1): 574.

https://doi.org/10.1182/blood-2023-181054

Published: 2023

Journal Articles

Patient-Reported Improvements in Fatigue and Health-Related Quality of Life in the Phase 3 Studies Apply-PNH and Appoint-PNH Evaluating the Use of Iptacopan in C5 Inhibitor-Treated and Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria

Antonio M Risitano, Carlos M de Castro, Bing Han, Austin Kulasekararaj, Jaroslaw P. Maciejewski, Phillip Scheinberg, Yasutaka Ueda, Susan Vallow, Georgina Bermann, Marion Dahlke, Rakesh Kumar, Regis Peffault de Latour

Blood (2023) 142 (Supplement 1): 487.

https://doi.org/10.1182/blood-2023-179035

Published: 2023

Journal Articles

A Real-World Evidence Review of Post-Marketing Safety and Compliance with Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the US

Carlos M de Castro, David Dingli, Mohammed Al-Adhami, Brian Mulherin, Michael Yeh, Stacie Lallier, Jesse Fishman

Blood (2023) 142 (Supplement 1): 5647.

https://doi.org/10.1182/blood-2023-181917

Published: 2023

Journal Articles

Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study

Blood (2022) 140 (Supplement 2): LBA-2.

https://doi.org/10.1182/blood-2022-171469

Published: 2022

Journal Articles

Addressing Clinical Management Challenges in the Treatment of Rare, Non-Malignant Hematologic Disorders through Educational Interventions

Sumera Ackbarali, Tariqa Ackbarali, Katie Kowalski, Hans C. Lee, Vaishali Sanchorawala, Shirley D'Sa, Satheesh Chonat, Carlos M. de Castro

Blood (2022) 140 (Supplement 1): 13057–13058.

https://doi.org/10.1182/blood-2022-157219

Published: 2022

Journal Articles

Effect of Pegcetacoplan on Quality of Life in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Pegasus Phase 3 Trial Comparing Pegcetacoplan to Eculizumab

Alexander Röth, MD, Britta Hoechsmann, Morag Griffin, MBChB, FRCPath, Carlos M. de Castro, MD, Jeffrey Szer, MBBS, Kensuke Usuki, MD PhD, Juliette Soret, MD, Mohamed Hamdani, MS, Temitayo Ajayi, Sujata P. Sarda, PhD, Jens Panse, MD

Blood (2020) 136 (Supplement 1): 10–12.

https://doi.org/10.1182/blood-2020-134581

Published: 2020

Journal Articles

Categorized Hematologic Response to Pegcetacoplan Versus Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Post Hoc Analysis of Data from a Phase 3 Randomized Trial (PEGASUS)

Antonio Risitano, Ilene C. Weitz, Carlos M. de Castro, MD, Jean-Jacques Kiladjian, Morag Griffin, MBChB, FRCPath, Hisakazu Nishimori, MD PhD, Mohamed Hamdani, Temitayo Ajayi, Scott B. Baver, PhD, Regis Peffault De Latour, MD PhD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-142166

Published: 2020

Journal Articles

Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria

Peter Hillmen, MBChB, PhD, Jeffrey Szer, MBBS, Ilene C. Weitz, Alexander Röth, MD, Britta Hoechsmann, Jens Panse, MD, Kensuke Usuki, MD PhD, Morag Griffin, MBChB, FRCPath, Jean-Jacques Kiladjian, MD PhD, Carlos M. de Castro, MD, Hisakazu Nishimori, MD PhD, Lisa Tan, Mohamed Hamdani, Pascal Deschatelets, PhD, Cedric Francois, MD PhD, Federico Grossi, MD, Antonio Risitano, Regis Peffault De Latour, MD PhD

Blood (2020) 136 (Supplement 1): 35–37.

https://doi.org/10.1182/blood-2020-142174

Published: 2020

Journal Articles

Pegcetacoplan Is Superior to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Regardless of Prior Transfusion Requirement

Regis Peffault De Latour, MD PhD, Carlos M. de Castro, MD, Jeffrey Szer, MBBS, Kensuke Usuki, MD PhD, Peter Hillmen, MBChB, PhD, Morag Griffin, MBChB, FRCPath, Mohamed Hamdani, MS, Temitayo Ajayi, Hisakazu Nishimori, MD PhD, Ilene C. Weitz

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-141061

Published: 2020

Journal Articles

Clinical Outcomes of Microtransplantation for Older Adults with Acute Myeloid Leukemia

Anthony D. Sung, MD, Carlos M. de Castro, MD, Thomas W. LeBlanc, MD MA, Gwynn D. Long, MD, Donna B. Adams, NP, Danielle M. Brander, MD, Sandeep Dave, MD, Louis F. Diehl, MD, Phuong Linh Doan, MD, Therese Hennig, PA, Yubin Kang, MD, Matthew S. McKinney, MD, Lindsay A.M Rein, MD, Dorothy A. Sipkins, MD, Yiping Yang, MD PhD, Nelson J. Chao, MDM.B.A, David A. Rizzieri, MD

Blood (2017) 130 (Supplement 1): 3853.

https://doi.org/10.1182/blood.V130.Suppl_1.3853.3853

Published: 2017

Journal Articles

Re-Induction Therapy Decisions Based on Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia,

Tod A. Morris, MD, David A. Rizzieri, MD, Carlos M de Castro, MD, Louis F. Diehl, MD, Jon P. Gockerman, MD, Anand S. Lagoo, MD, PhD, Joseph O. Moore, MD, Arati V Rao, MD

Blood (2011) 118 (21): 3590.

https://doi.org/10.1182/blood.V118.21.3590.3590

Published: 2011

Journal Articles

SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target

Dale J. Christensen, Youwei Chen, Jessica Oddo, Karen M. Matta, Jessica Neil, Evan D. Davis, Alicia D. Volkheimer, Mark C. Lanasa, Daphne R. Friedman, Barbara K. Goodman, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Michael P. Vitek, J. Brice Weinberg

Blood (2011) 118 (15): 4150–4158.

https://doi.org/10.1182/blood-2011-04-351072

Published: 2011

Includes: Supplemental data

Journal Articles

The SET Oncogene, a Potent PP2A Inhibitor, Is Elevated in CLL and Antagonism of SET Induces Apoptosis.

Dale J. Christensen, PhD, Karen M. Bond, BS, Alicia D. Volkheimer, MS, Jessica Oddo, BS, Youwei Chen, MD, Jon P. Gockerman, MD, Joseph O. Moore, MD, Louis F. Diehl, MD, Carlos M. de Castro, MD, Michael P. Vitek, PhD, J. Brice Weinberg, MD

Blood (2009) 114 (22): 802.

https://doi.org/10.1182/blood.V114.22.802.802

Published: 2009

Journal Articles

Maintenance Therapy with Low-Dose Subcutaneous 5-Azacitidine in Older Patients with AML in 1st Remission.

Jeffrey E Lancet, MD, Rami S. Komrokji, MD, HuiYi Lin, Carlos M. de Castro, MD, David A. Rizzieri, Magda Melchert, Alan F List, MD

Blood (2009) 114 (22): 1029.

https://doi.org/10.1182/blood.V114.22.1029.1029

Published: 2009

Journal Articles

Apolipoprotein E-Mimetic Therapeutic Peptides Mediate CLL Cell Cytotoxicity

Blood (2008) 112 (11): 359.

https://doi.org/10.1182/blood.V112.11.359.359

Published: 2008

Journal Articles

Cytotoxicity of the Type 4 Phosphodiesterase Inhibitor CD160130 for Freshly Isolated Human CLL Cells In Vitro.

J. Brice Weinberg, MD, Ning Jiang, MD, Alicia D. Volkheimer, MS, Youwei Chen, MD, Karen M. Bond, BS, Joseph O. Moore, MD, Jon P. Gockerman, MD, Louis F. Diehl, MD, Carlos M. de Castro, MD, David A. Rizzieri, MD, PhD, Marc C. Levesque, MD, PhD, Kenneth Mugridge, PhD, Joe DeAngelo

Blood (2007) 110 (11): 3129.

https://doi.org/10.1182/blood.V110.11.3129.3129

Published: 2007

Journal Articles

MicroRNA Expression in Red Blood Cells from Patients with PNH.

Jen-Tsan Ashley Chi, PhD, Carolyn Sangokoya, Carlos M. de Castro, M.D.

Blood (2007) 110 (11): 3675.

https://doi.org/10.1182/blood.V110.11.3675.3675

Published: 2007

Journal Articles

Apolipoprotein E (APOE) Genotype as a Determinant of Survival in Women with Chronic Lymphocytic Leukemia.

J. Brice Weinberg, MD, Alicia D. Volkheimer, MS, Mirta Mihovilovic, PhD, Ning Jiang, MD, Youwei Chen, MD, Joseph O. Moore, MD, Jon P. Gockerman, MD, Louis F. Diehl, MD, Carlos M. de Castro, MD, David A. Rizzieri, MD, Marc C. Levesque, MD, PhD, Robert DeKroon, PhD, Warren J. Strittmatter, MD

Blood (2007) 110 (11): 3081.

https://doi.org/10.1182/blood.V110.11.3081.3081

Published: 2007

NARROW

Challenges in PNH and CAD Management Revealed through Educational Interventions over Three Years

Patient Satisfaction with Use of Complement Inhibitor Injector in Paroxysmal Nocturnal Hemoglobinuria in the United States

Efficacy and Safety Is Maintained in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan for up to 3 Years

Patient-Reported Improvements in Fatigue and Health-Related Quality of Life in the Phase 3 Studies Apply-PNH and Appoint-PNH Evaluating the Use of Iptacopan in C5 Inhibitor-Treated and Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria

A Real-World Evidence Review of Post-Marketing Safety and Compliance with Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the US

Addressing Clinical Management Challenges in the Treatment of Rare, Non-Malignant Hematologic Disorders through Educational Interventions

Effect of Pegcetacoplan on Quality of Life in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Pegasus Phase 3 Trial Comparing Pegcetacoplan to Eculizumab

Categorized Hematologic Response to Pegcetacoplan Versus Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Post Hoc Analysis of Data from a Phase 3 Randomized Trial (PEGASUS)

Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria

Pegcetacoplan Is Superior to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Regardless of Prior Transfusion Requirement

Clinical Outcomes of Microtransplantation for Older Adults with Acute Myeloid Leukemia

Re-Induction Therapy Decisions Based on Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia,

SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target

The SET Oncogene, a Potent PP2A Inhibitor, Is Elevated in CLL and Antagonism of SET Induces Apoptosis.

Maintenance Therapy with Low-Dose Subcutaneous 5-Azacitidine in Older Patients with AML in 1st Remission.

Apolipoprotein E-Mimetic Therapeutic Peptides Mediate CLL Cell Cytotoxicity

Cytotoxicity of the Type 4 Phosphodiesterase Inhibitor CD160130 for Freshly Isolated Human CLL Cells In Vitro.

MicroRNA Expression in Red Blood Cells from Patients with PNH.

Apolipoprotein E (APOE) Genotype as a Determinant of Survival in Women with Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only